

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6203873

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
HENRI GAUTHIER	10/22/2018
NICOLAS TILATTI	10/22/2018
PHILIPPE COURTIADÉ	10/22/2018
RECEIVING PARTY DATA	
Name:	HEMO PLUS SÀRL
Street Address:	RUE DU GRAND-PONT 18
City:	LAUSANNE
State/Country:	SWITZERLAND
Postal Code:	1003
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16930770
CORRESPONDENCE DATA	
Fax Number:	(603)226-7499
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(603)226-7490
Email:	tclark@nhpat.com
Correspondent Name:	DAVIS & BUJOLD P.L.L.C.
Address Line 1:	112 PLEASANT STREET
Address Line 4:	CONCORD, UNITED STATES 03301
ATTORNEY DOCKET NUMBER:	ACTOSP P03AUSC1
NAME OF SUBMITTER:	MICHAEL J. BUJOLD
SIGNATURE:	/Michael J. Bujold/
DATE SIGNED:	07/16/2020
This document serves as an Oath/Declaration (37 CFR 1.63).	
Total Attachments: 2	
source=p03ausc1.dec_ass#page1.tif	
source=p03ausc1.dec_ass#page2.tif	

COMBINED OATH/DECLARATION/
ASSIGNMENT OF INVENTION

ACTOSP P03AUS

For: ☒ U.S. and/or ☐ Foreign Rights
For: ☒ U.S. Application or ☐ U.S. Patent
By: ☒ Inventor(s) or ☐ Present Owner

In consideration of the payment by ASSIGNEE to ASSIGNORS of the sum of One Dollar (\$1.00), the receipt of which is hereby acknowledged, and for other good and valuable consideration, ASSIGNORS:

Henri GAUTHIER
32 Place Mage
31000 Toulouse
FRANCE

Nicolas TILATTI
Jonquières, La Falistres
47550 Boe
FRANCE

Philippe COURTIADÉ
32, chemin de Quint
31280 Aigrefeuille
FRANCE

hereby sell, assign and transfer to ASSIGNEE:

HEMO PLUS SARL
Rue du Grand-Pont 18
1003 Lausanne
SWITZERLAND

and the successors, assigns and legal representatives of the ASSIGNEE

- ☒ the entire right, title and interest in the United States of America
☐ and in all foreign countries, including all rights to claim priority,

in and to any and all improvements which are disclosed in the invention entitled **SELF-CONTAINED TREATMENT UNIT FOR HAEMODIALYSIS TREATMENTS** and which is found in:

- ☐ U.S. Application being filed concurrently herewith; or
☒ U.S. Application serial no. PCT/CH2017/000070 filed with an effective date of July 4, 2017

and, in and to, all Letters Patent to be obtained for said invention by the above application/patent or any continuation(s), division(s), renewal(s), or substitute(s) thereof, and as to the Letters Patent concerning any reissue or re-examination thereof;

ASSIGNORS hereby covenant that no assignment, sale, agreement or encumbrance has been, or will be made or entered into, which would conflict with this assignment;

ASSIGNORS further covenant that ASSIGNEE will be promptly provided, upon ASSIGNEE's request, with all pertinent facts and documents relating to said invention and said Letters Patent and any legal equivalents thereof as may be known and/or accessible to ASSIGNORS and will testify about the same in any interference, litigation or other proceeding related thereto and will promptly execute and deliver to ASSIGNEE,

or its legal representatives, any and all papers, instruments and/or affidavits required to apply for, obtain, maintain, issue and/or enforce said patent application, said invention and said Letters Patent and/or any equivalents thereof which may be necessary or desirable to carry out the purposes thereof without any further consideration of any kind being required to be paid by ASSIGNEE.

OATH/DECLARATION

The above identified application was made or authorized to be made by us, the ASSIGNORS of this invention.


We, the ASSIGNORS, believe each named joint inventor to be an original joint inventor of the claimed invention in the application for which this declaration is being submitted.

We, the ASSIGNORS, reviewed and understand the contents of the application, including the claims as originally filed or any claim amendment(s) specifically referred to herein, and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to us to be material to patentability, as defined in 37 CFR § 1.56.


We, the ASSIGNORS, hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both and may jeopardize the validity of the application or any patent issuing thereon. We further acknowledge that all statements made herein of our own knowledge are true and all statements made on information and belief are believed to be true.

IN WITNESS WHEREOF, We have hereunto set hand this

Date: 22/10/2018


Henri GAUTHIER

Date: 22/10/2018


Nicolas TILATTI

Date: 22/10/2018


Philippe COURTIADÉ